Bibliography
- Yanagisawa M , KuriharaH, KimuraSet al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature332, 411–415 (1988).
- Dammanahalli KJ , SunZ: Endothelins and NADPH oxidases in the cardiovascular system.Clin. Exp. Pharmacol. Physiol.35, 2–6 (2008).
- Makita T , SucovHM, GariepyCE, YanagisawaM, GintyDD: Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons.Nature452, 759–763 (2008).
- Clozel M , BreuV, BurriKet al.: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist.Nature365, 759–761 (1993).
- Roux S , BreuV, GillerTet al.: Ro 61–1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm.J. Pharmacol. Exp. Ther.283, 1110–1118 (1997).
- Vuurmans JL , BoerP, KoomansHA: Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans.Nephrol. Dial. Transplant.19, 2742–2746 (2004).
- Vuurmans TJ , BoerP, KoomansHA: Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans.Hypertension41, 1253–1258 (2003).
- van Giersbergen PL , DingemanseJ: Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.Eur. J. Clin. Pharmacol.63, 151–158 (2007).
- Treinen KA , LoudenC, DennisMJ, WierPJ: Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits.Teratology59, 51–59 (1999).
- van Giersbergen PL , DingemanseJ: Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.Clin. Drug Investig.27, 797–802 (2007).
- van Giersbergen PL , GunawardenaKA, DingemanseJ: Influence of ethnic origin and sex on the pharmacokinetics of clazosentan.J. Clin. Pharmacol.47, 1374–1380 (2007).
- Macdonald RL , KassellNF, MayerSet al.: Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled Phase 2 dose-finding trial.Stroke39(11), 3015–3021 (2008).
- van Giersbergen PL , VajkoczyP, MeyerBet al.: A pharmacokinetic study of clazosentan in patients with aneurysmal subarachnoid hemorrhage.Acta Neurochir. Suppl. (Wien)104, 125–126 (2008).
- van Giersbergen PL , DingemanseJ: Pharmacokinetic and pharmacodynamic aspects of the interaction between clazosentan and nimodipine in healthy subjects.Acta Neurochir. Suppl. (Wien)104, 127–130 (2008).
- Macdonald RL , PlutaRM, ZhangJH: Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution.Nat. Clin. Pract. Neurol.3, 256–263 (2007).
- Armstead WM : Endothelins and the role of endothelin antagonists in the management of posttraumatic vasospasm.Curr. Pharm. Des.10, 2185–2192 (2004).
- Vatter H , ZimmermannM, TesanovicV, RaabeA, SchillingL, SeifertV: Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist clinically effective for the treatment of cerebral vasospasm. Part I: inhibitory effect on endothelin(A) receptor-mediated contraction.J. Neurosurg.102, 1101–1107 (2005).
- Vatter H , ZimmermannM, TesanovicV, RaabeA, SeifertV, SchillingL: Cerebrovascular characterization of clazosentan, the first nonpeptide endothelin receptor antagonist shown to be clinically effective for the treatment of cerebral vasospasm. Part II: effect on endothelin(B) receptor-mediated relaxation.J. Neurosurg.102, 1108–1114 (2005).
- Hino A , TokuyamaY, KobayashiMet al.: Increased expression of endothelin B receptor mRNA following subarachnoid hemorrhage in monkeys.J. Cereb. Blood Flow Metab.16, 688–697 (1996).
- Fergusen S , MacdonaldRL: Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage.Neurosurgery60, 658–667 (2007).
- Nolan CP , MacdonaldRL: Can angiographic vasospasm be used as a surrogate marker in evaluating therapeutic interventions for cerebral vasospasm?Neurosurg. Focus21, E1 (2006).
- Hauck EF , HoffmannJF, HeimannA, KempskiO: EndothelinA receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils.Brain Res.1157, 138–145 (2007).
- Henriksson M , StenmanE, VikmanP, EdvinssonL: Protein kinase C inhibition attenuates vascular ETB receptor upregulation and decreases brain damage after cerebral ischemia in rat.BMC Neurosci.8, 7 (2007).
- Dawson DA , SuganoH, McCarronRM, HallenbeckJM, SpatzM: Endothelin receptor antagonist preserves microvascular perfusion and reduces ischemic brain damage following permanent focal ischemia.Neurochem. Res.24, 1499–1505 (1999).
- Bhardwaj A , WuY, HurnPD, KirschJR, TraystmanRJ: Administration of selective endothelin receptor type A antagonist Ro 61–1790 does not improve outcome in focal cerebral ischemia in cat.J. Cereb. Blood Flow Metab.20, 499–504 (2000).
- Sato M , NobleLJ: Involvement of the endothelin receptor subtype A in neuronal pathogenesis after traumatic brain injury.Brain Res.809, 39–49 (1998).
- Gorlach C , HortobagyiT, HortobagyiS, BenyoZ, WahlM: Inhibition of endothelin-1 by the competitive ETA receptor antagonist Ro 61–1790 reduces lesion volume after cold injury in the rat.Pflugers Arch.441, 844–849 (2001).
- Weyer GW , NolanCP, MacdonaldRL: Evidence-based cerebral vasospasm management.Neurosurg. Focus21, E8 (2006).
- Shaw MD , VermeulenM, MurrayGD, PickardJD, BellBA, TeasdaleGM: Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group.J. Neurosurg.93, 992–997 (2000).
- Hino A , WeirBK, MacdonaldRL, ThistedRA, KimCJ, JohnsLM: Prospective, randomized, double-blind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys.J. Neurosurg.83, 503–509 (1995).
- Knekt P , ReunanenA, AhoKet al.: Risk factors for subarachnoid hemorrhage in a longitudinal population study.J. Clin. Epidemiol.44, 933–939 (1991).
- Vajkoczy P , MeyerB, WeidauerSet al.: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.J. Neurosurg.103, 9–17 (2005).
- Hunt WE , HessRM: Surgical risk as related to time of intervention in the repair of intracranial aneurysms.J. Neurosurg.28, 14–20 (1968).
- Barth M , CapelleHH, MunchEet al.: Effects of the selective endothelin A (ETA) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage – preliminary results from a randomized clinical series.Acta Neurochir. (Wien)149, 911–918 (2007).